Clinical trials: Pancreatic Metastatic Cancer
Pancreatic Cancer, Advanced or Metastatic
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer
The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood test.
- Trial name
- NCT07528430
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- University of Maryland, Baltimore
NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to…
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer
- Trial name
- NCT03207867
- Testing
- NIR178, PDR001
- Where
- 21 sites in United States, Argentina and 13 more
- Volunteers
- 315 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreatic Adenocarcinoma
A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of…
- Trial name
- NCT05484011
- Testing
- odetiglucan, CDX-1140
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- HiberCell, Inc.
Metastatic Pancreatic Cancer
Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.
Retrospective, multicenter study including pts with metastatic pancreatic cancer who started first-line treatment with napaclitaxel plus Gemcitabine between December 2013 and June 2015 according to the routine practice.
- Trial name
- ANICE-PaC (NCT03620461)
- Testing
- Gemcitabine - nabpaclitaxel
- Volunteers
- 210 people
- Sponsor
- Galician Research Group on Digestive Tumors
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to understand whether a blood-based test called circulating tumor DNA (ctDNA) can detect whether participants are having a desired tumor shrinkage or an undesired lack of tumor shrinkage, and to study…
- Trial name
- NCT07096362
- Testing
- 5-Fluorouracil, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Miami
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Metastatic Pancreatic Ductal Adenocarcinoma
Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a phase III, multi-center study to evaluate the efficacy and safety of chiauranib plus plus toripalimab, albumin-paclitaxel and gemcitabine as first-line therapy in patients with metastatic pancreatic ductal…
- Trial name
- NCT07445295
- Testing
- Chiauranib, Toripalimab Injection, Albumin-paclitaxel Injection
- Where
- China
- Volunteers
- 558 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Pancreatic Cancer, Unresectable Pancreatic Cancer
Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
- Conditions
- Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT05657743
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- 2 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Alpha Tau Medical LTD.
Pancreatic Neoplasm, Digestive System Neoplasm
OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.
The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSil™ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination…
- Conditions
- Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
- Trial name
- OSPREY (NCT04493632)
- Where
- 9 sites in Spain, United Kingdom
- Volunteers
- 500 people
- Sponsor
- OncoSil Medical Limited
Pancreas Cancer
Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer
Patients with non-resectable pancreatic cancer have a poor prognosis.The analysis of prognostic factors before treatment may be helpful in selecting appropriate candidates for chemotherapy and determining treatment strategies.
- Trial name
- PEACE (NCT03513198)
- Testing
- Endoscopic ultrasound (including fine needle aspiration), Contrast-enhanced endoscopic ultrasound (CE-EUS), Endoscopic ultrasound elastography (EG-EUS)
- Volunteers
- 200 people
- Sponsor
- University of Medicine and Pharmacy Craiova
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
This phase II trial studies the effect of standard of care chemotherapy with or with out stereotactic body radiation therapy in treating patients with pancreatic cancer that has spread to a limited amount of places in the body…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04975516
- Testing
- Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Pancreatic Adenocarcinoma Metastatic, Liver Metastasis
NH002-mediated Sonoporation With Chemotherapy in Advanced Pancreatic Cancer
This is a phase I study that will enroll patients with pancreatic cancer and liver metastasis who have failed prior gemcitabine-based chemotherapy.
- Trial name
- NCT07314385
- Testing
- nanoliposomal irinotecan+5-FU+leucovorin, NH002 (Perflutren Lipid Microspheres) Injectable Suspension, Aco Apache Ultrasound
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Cancer, Pancreatic Cancer Metastatic
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC).
- Trial name
- NCT07549958
- Testing
- Pitavastatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, Irvine
Pancreatic Cancer
First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer
Primary objective: to evaluate whether the addition of sunitinib prolongates the Progression-Free Survival (PFS) in patients with advanced pancreatic cancer receiving first-line gemcitabine chemotherapy.
- Trial name
- NCT00673504
- Testing
- Gemcitabine + Sunitinib, Gemcitabine
- Where
- 11 sites in Germany, Switzerland
- Volunteers
- 105 people
- Sponsor
- Central European Society for Anticancer Drug Research
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1)
Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer
This is a research study in 2 parts assessing the following parameters of the combination of the study drug called bosutinib, and a drug called capecitabine: the safety, how well the subject's body handles the study drug, and…
- Conditions
- Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1)
- Trial name
- NCT00959946
- Testing
- Bosutinib, Capecitabine
- Where
- 7 sites in United States, Australia and 4 more
- Volunteers
- 32 people
- Sponsor
- Pfizer
Colorectal Cancer, Pancreatic Cancer
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies
This is a multicenter, single arm, 3-cohort, open-label trial of high dose Vitamin C intravenous infusion in subjects with solid tumor malignancies who are eligible for resection (cohort A) or with extended RAS (e.g.KRAS or NRAS)…
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT03146962
- Testing
- Vitamin C
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Weill Medical College of Cornell University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
This phase II trial studies how well fludarabine phosphate, cyclophosphamide, total body irradiation, and donor stem cell transplant work in treating patients with blood cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03333486
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Roswell Park Cancer Institute
Kidney Cancer, Head and Neck Cancer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT00967577
- Testing
- 177Lu-J591
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Breast Neoplasms, Pancreatic Neoplasms
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast…
- Trial name
- NCT02309177
- Testing
- nab-Paclitaxel, Nivolumab, Gemcitabine
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Celgene
Breast Cancer, Colorectal Cancer
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
RATIONALE: Counting the number of circulating cancer cells in samples of blood from patients with metastatic cancer may help doctors find out how much the cancer has spread.
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer
- Trial name
- NCT00898781
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.